Novavax Inc. (NVAX)
COVID-19 Vaccine Maker Novavax Trims Annual Outlook As Q2 Sales Take A Hit
On Thursday, Novavax Inc NVAX reported second-quarter 2024 sales of $415 million, compared to $424 million a year, missing the consensus of $458.6 million.
Novavax (NVAX) Misses Q2 Earnings and Revenue Estimates
Novavax (NVAX) came out with quarterly earnings of $0.99 per share, missing the Zacks Consensus Estimate of $1.82 per share. This compares to earnings of $0.58 per share a year ago.
Novavax quarterly revenue misses estimate on weak COVID vaccine sales
Novavax reported second-quarter revenue that was below analysts' estimates on Thursday due to lower-than-expected sales of its COVID-19 vaccine.
Novavax (NVAX) Stock Before Q2 Earnings: To Buy or Not to Buy?
On Novavax's (NVAX) second-quarter earnings call, investors will likely focus on the company's pipeline updates and collaboration revenue numbers from its recently entered deal with Sanofi.
Where Will Novavax Be in 5 Years?
Novavax's business has improved over the past 18 months. The company has several important catalysts and potential growth drivers.
Novavax (NVAX) Registers a Bigger Fall Than the Market: Important Facts to Note
The latest trading day saw Novavax (NVAX) settling at $12.57, representing a -1.87% change from its previous close.
JPMorgan Just Issued a Warning on Novavax (NVAX) Stock
Vaccine manufacturer Novavax (NASDAQ: NVAX ) is falling on Tuesday following a major sentiment downgrade. Indeed, analysts at JPMorgan warned that NVAX stock has exceeded the true value it can extract from its Covid-19 vaccine.
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Novavax Ahead Of Q2 Earnings - Picking Apart The Sanofi Deal
Novavax's Q1 2024 earnings were so-so, but a major partnership with Sanofi sent its share price soaring by 200%. The Sanofi deal provides essential funding but restricts Novavax's future earning potential, making it reliant on revenue streams from Sanofi. Novavax's long-term prospects may be challenging as it may struggle to develop new products and could see its revenue streams dry up post-2025.
Novavax's (NVAX) Shares Surge 211% YTD: Time to Buy the Stock?
Novavax's (NVAX) shares continue to soar thanks to the recently signed partnership with Sanofi (SNY) to market its COVID-19 vaccine and develop novel COVID-19-influenza combination vaccines.
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Wall Street Bulls Look Optimistic About Novavax (NVAX): Should You Buy?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
